Cardiovascular drug might treat diabetic retinopathy

Article

A drug that has traditionally been used to treat cardiovascular conditions has shown promise in the treatment and prevention of diabetic retinopathy. The claim was based on data from a large-scale programme assessing the effect of an angiotensin receptor blocker (ARB) on the incidence and progression of diabetic eye disease. Findings from the study will be published in The Lancet.

A drug that has traditionally been used to treat cardiovascular conditions has shown promise in the treatment and prevention of diabetic retinopathy. The claim was based on data from a large-scale programme assessing the effect of an angiotensin receptor blocker (ARB) on the incidence and progression of diabetic eye disease. Findings from the study will be published in The Lancet.

The data, from over 5,000 patients, showed that the ARB, candesartan, caused a reduction in the incidence of diabetic retinopathy in type 1 diabetic patients, although this did not reach statistical significance, and a significant increase in regression of diabetic retinopathy in type 2 diabetics.

The DIRECT programme was a multicentre study, following 5,231 diabetic patients for at least four years, across 309 centres in 30 countries.

In type 1 patients with no signs of diabetic retinopathy at baseline, candesartan caused an 18% reduction in the incidence of disease as measured by 2-step change on the ETDRS scale, but a 35% reduction for 3-step change. Meanwhile, it increased the probability of disease regression by 34% in type 2 patients with early signs of retinopathy, whilst reducing the overall risk of progression by 13% in type 2 patients.

Around 80% of patients enrolled were treated for four to six years on a dose of 32 mg candesartan. The findings were presented in September at the European Association of the Study of Diabetes congress in Rome, Italy.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.